Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Dec;11(4):275-80.
doi: 10.1007/s11154-010-9138-0.

Compliance and persistence with osteoporosis medications: a critical review of the literature

Stuart Silverman  1 , Deborah T Gold
Affiliations
Review

Compliance and persistence with osteoporosis medications: a critical review of the literature

Stuart Silverman et al. Rev Endocr Metab Disord. 2010 Dec.

Abstract

It is widely acknowledged that compliance and persistence with oral osteoporosis medications, particularly with bisphosphonates, is poor. Several excellent reviews have been written on compliance and persistence with osteoporosis medications and have discussed improvements seen with extended dosing intervals. This review begins with studies on extended dosing intervals to examine the limitations of administrative claims data. It also looks at compliance and persistence across multiple medical conditions, examining the importance of prescription fulfillment, intentional choice, causation and possible interventions.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013–22. doi: 10.4065/81.8.1013. - DOI - PubMed
    1. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922–8. doi: 10.1016/j.bone.2005.10.022. - DOI - PubMed
    1. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:811–8. doi: 10.1007/s00198-007-0506-x. - DOI - PubMed
    1. Grainger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic renal failure in the CHARM program, double-blind randomized controlled trial. Lancet. 2005;366:2005–11. doi: 10.1016/S0140-6736(05)67760-4. - DOI - PubMed
    1. Rasmussen JIN, Chong A, Alter DA. 2007 Relationship between adherence to evidence-based pharmacotherapy and long term mortality of people with myocardial infarctions. JAMA. 2007;297(2):177–86. doi: 10.1001/jama.297.2.177. - DOI - PubMed

MeSH terms

Substances